Endocrinology News

On May 8, the health care organization Ascension experienced a cyberattack that disrupted access to its electronic health care records, patient portals, phones and systems used to order tests, medications and procedures.

Financial independence is the holy grail, which affords one to work for the sake of working with the peace of mind of knowing they are no longer dependent on a paycheck to maintain their lifestyle.

BOSTON — Pregnant and reproductive-aged women have had recent declines in exposure to most endocrine-disrupting chemicals, though women with a lower socioeconomic status are exposed to higher chemical levels, according to a speaker.

PHILADELPHIA — HDL cholesterol has not been shown to have a causal role in atherosclerotic cardiovascular disease, nor has lowering it reduced CV outcomes, but it may serve as a marker for CVD risk, according to a speaker.

PHILADELPHIA — In this Healio video exclusive, Yehuda Handelsman, MD, FACP, FNLA, FASCP, MACE, presents updated multispecialty practice recommendations for diabetes, cardiorenal and metabolic diseases at the Heart in Diabetes CME Conference.

PHILADELPHIA — In this Healio video exclusive, Neha J. Pagidipati, MD, MPH, highlights growing evidence on the relationship between weight change and risk for cardiovascular disease.

Among pediatric patients with homozygous familial hypercholesterolemia and elevated LDL despite optimal lipid-lowering therapy, evinacumab durably reduced LDL and other significant lipid parameters out to 72 weeks, a speaker reported.

Prevention of heart disease will do more good in the long run than procedures to treat advanced heart disease, the incoming president of National Lipid Association said at the NLA’s Scientific Sessions.

Adults with hypoparathyroidism experience declines in cognitive function that may be due to structural changes in the brain, according to findings published in the Journal of Bone and Mineral Research.

Patients who were prescribed phentermine after losing fewer than 20 pounds while on a GLP-1 receptor agonist were more likely to lose weight 1 year after GLP-1 discontinuation than those who were not prescribed phentermine, recent findings show.